Related Experiment Video
Updated: May 21, 2026
12:55
Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells
Published on: October 10, 2017
Curcuminoids in neurodegenerative diseases.
Darrick S H L Kim1, Jin Y Kim, Yesun Han
1Core LifeSource Inc., 5100 Newport Dr. Suite # 10, Rolling Meadows, IL 60008, USA. calebin@gmail.com
Recent Patents on CNS Drug Discovery
|June 30, 2012
Summary
Curcuminoids, compounds from turmeric, show potential in treating neurodegenerative diseases like Alzheimer's and Parkinson's by reducing inflammation and protein aggregation. Further research and improved bioavailability are key for therapeutic development.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Neurodegenerative diseases involve progressive neuron deterioration, sharing common biochemical pathways.
- Diseases include Alzheimer's, Parkinson's, ALS, and others, impacting the central nervous system.
- Curcuminoids, from turmeric, exhibit diverse biological properties relevant to neuroprotection.
Purpose of the Study:
- To review the therapeutic potential of curcuminoids against various neurodegenerative diseases.
- To highlight curcuminoids' mechanisms in modulating neurodegenerative processes.
- To discuss the development of curcuminoid-based therapies.
Main Methods:
- Literature review of studies on curcuminoids and neurodegenerative diseases.
- Analysis of curcuminoids' effects on biochemical pathways like oxidative stress and inflammation.
- Examination of curcuminoids' interactions with disease-specific proteins (e.g., Aβ, α-synuclein).
Main Results:
- Curcuminoids attenuate oxidative stress and inflammation in Alzheimer's disease models.
- They inhibit β-amyloid plaque and α-synuclein aggregation, relevant to Alzheimer's and Parkinson's.
- Curcuminoids show promise for treating multiple sclerosis, diabetic encephalopathy, and neurodamages.
Conclusions:
- Curcuminoids demonstrate significant potential as therapeutic agents for a range of neurodegenerative conditions.
- Modulating key pathological mechanisms like protein aggregation and inflammation is crucial.
- Improving curcuminoid bioavailability is essential for successful therapeutic application.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...